Table of Contents
Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Solid Tumors Market in Asia Pacific to 2019 - Introduction
2.1 Introduction
3 Solid Tumors Market in Asia Pacific to 2019 - Therapeutic Landscape
3.1 Bladder Cancer
3.1.1 Symptoms
3.1.2 Etiology
3.1.3 Pathophysiology
3.1.4 Diagnosis
3.1.5 Classification
3.1.6 Epidemiology
3.1.7 Prognosis and Disease Staging
3.1.8 Treatment Options
3.2 Ovarian Cancer
3.2.1 Symptoms
3.2.2 Etiology
3.2.3 Pathophysiology
3.2.4 Diagnosis
3.2.5 Classification
3.2.6 Epidemiology
3.2.7 Prognosis and Disease Staging
3.2.8 Treatment Options
3.3 Pancreatic Cancer
3.3.1 Symptoms
3.3.2 Etiology
3.3.3 Pathophysiology
3.3.4 Diagnosis
3.3.5 Classification
3.3.6 Epidemiology
3.3.7 Prognosis and Disease Staging
3.3.8 Treatment Algorithm
3.4 Prostate Cancer
3.4.1 Symptoms
3.4.2 Etiology
3.4.3 Pathophysiology
3.4.4 Co-Morbidities and Complications
3.4.5 Diagnosis
3.4.6 Classification
3.4.7 Epidemiology
3.4.8 Prognosis and Disease Staging
3.4.9 Treatment Options
4 Solid Tumors Market in Asia Pacific to 2019 - Marketed Products
4.1 Bladder Cancer
4.2 Ovarian Cancer
4.3 Pancreatic Cancer
4.4 Prostate Cancer
4.5 Key Marketed Products
4.5.1 Carboplatin
4.5.2 Cisplatin
4.5.3 Gemcitabine
4.5.4 Paclitaxel
4.5.5 Doxorubicin
4.5.6 Avastin (bevacizumab)
4.5.7 Tarceva (erlotinib)
4.5.8 Sutent (sunitinib)
4.5.9 Afinitor (everolimus)
4.5.10 Taxotere (docetaxel)
4.5.11 Zytiga (abiraterone acetate)
4.5.12 Jevtana (cabazitaxel)
5 Solid Tumors Market in Asia Pacific to 2019 - Pipeline Analysis
5.1 Bladder Cancer Pipeline
5.1.1 Overall Pipeline
5.1.2 Pipeline Analysis by Molecule Type
5.1.3 Pipeline Analysis by Mechanism of Action
5.2 Ovarian Cancer Pipeline
5.2.1 Overall Pipeline
5.2.2 Pipeline Analysis by Molecule Type
5.2.3 Pipeline Analysis by Mechanism of Action
5.3 Pancreatic Cancer Pipeline
5.3.1 Overall Pipeline
5.3.2 Pipeline Analysis by Molecule Type
5.3.3 Pipeline Analysis by Mechanism of Action
5.4 Prostate Cancer Pipeline
5.4.1 Overall Pipeline
5.4.2 Pipeline Analysis by Molecule Type
5.4.3 Pipeline Analysis by Mechanism of Action
5.5 Promising Drug Candidates in the Pipeline
5.5.1 Abraxane (albumin-bound paclitaxel)
5.5.2 AMG 386 (trebananib)
5.5.3 Votrient (pazopanib)
5.5.4 Xtandi (enzalutamide)
6 Solid Tumors Market in Asia Pacific to 2019- Market Forecast
6.1 Asia-Pacific Market
6.1.1 Treatment Usage Patterns
6.1.2 Annual Cost of Treatment
6.1.3 Market Size
6.2 India
6.2.1 Treatment Usage Patterns
6.2.2 Annual Cost of Treatment
6.2.3 Market Size
6.3 Australia
6.3.1 Treatment Usage Patterns
6.3.2 Annual Cost of Treatment
6.3.3 Market Size
6.4 China
6.4.1 Treatment Usage Patterns
6.4.2 Annual Cost of Treatment
6.4.3 Market Size
6.5 Japan
6.5.1 Treatment Usage Patterns
6.5.2 Annual Cost of Treatment
6.5.3 Market Size
6.6 Drivers and Barriers for the Solid Tumors Market in APAC
6.6.1 Drivers
6.6.2 Barriers
7 Solid Tumors Market in Asia Pacific to 2019 - Deals and Strategic Consolidations
7.1 Deals Analysis
7.2 Major Co-Development Deals
7.2.1 ScinoPharm Taiwan and Coland Enter into Agreement to Develop Generic Oncological Drugs
7.2.2 Bind Biosciences Enters into Agreement with Amgen to Develop Cancer Drugs
7.2.3 Merck Enters into Co-Development Agreement with Endocyte for Cancer Drug
7.2.4 Merck Serono Enters into Co-Development Agreement with Threshold Pharma for TH-302,
Pancreatic Cancer Drug
7.2.5 Seattle Genetics Exercises Option for Co-Development Agreement with Agensys (affiliate of
Astellas) for ASG-15ME
7.3 Major Licensing Deals
7.3.1 Spectrum Pharma Amends Licensing Agreement with Allergan for Apaziquone
7.3.2 Chugai Pharma Enters Into Licensing Agreement with Debiopharm Group for FF284
7.3.3 Baxter International Enters into Licensing Agreement with Onconova Therapeutics for
Rigosertib
7.3.4 Dyax Enters Into Licensing Agreement with Kadmon for Oncology Drug
7.3.5 Medigene Extends Licensing Agreement with Syncore for EndoTAG-1
8 Solid Tumors Market in Asia Pacific to 2019 - Appendix
8.1 Pipeline Drugs by Phase
8.1.1 Phase III
8.1.2 Pre-registration/NDA-filed
8.2 Market Forecasts to 2018
8.2.1 APAC
8.2.2 Australia
8.2.3 China
8.2.4 India
8.2.5 Japan
8.3 Market Definitions
8.4 Abbreviations
8.5 Sources
8.6 Research Methodology
8.6.1 Coverage
8.6.2 Secondary Research
8.6.3 Primary Research
8.6.4 Therapeutic Landscape
8.6.5 Geographical Landscape
8.6.6 Pipeline Analysis
8.7 Expert Panel Validation
8.8 Contact Us
8.9 Disclaimer